Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
BlackRock, Inc. reports beneficial ownership of 4,578,650 shares (4.7%) of Solid Biosciences Inc. common stock as of 03/31/2026. The filing (Schedule 13G/A, CUSIP 83422E204) shows sole voting power of 4,515,473 and sole dispositive power of 4,578,650. The amendment was signed on 04/27/2026 by Spencer Fleming, Managing Director.
Solid Biosciences Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 10, 2026. The company seeks to elect three Class II directors to terms ending in 2029 and ratify the advisory appointment of co‑founder Ilan Ganot as a Class I director through 2028.
Stockholders are also asked to ratify PricewaterhouseCoopers LLP as auditor for 2026, approve an amendment doubling authorized common stock from 240,000,000 to 480,000,000, and cast an advisory “say‑on‑pay” vote on executive compensation. The record date is April 16, 2026, with 98,413,277 common shares entitled to one vote each.
Howton David T reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. reported that Chief Operating Officer David T. Howton received a grant of 79,341 restricted stock units (RSUs), each representing a contingent right to one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, where 25% of the target RSUs vest upon each of four predetermined performance milestones.
The Board determined that the second performance milestone was met on January 29, 2026, triggering this portion of the award. The shares tied to this milestone are scheduled to vest in the first quarter of 2027, subject to Mr. Howton’s continued service with the company on the evaluation date. This is a compensation-related equity award, not an open-market stock purchase.
Brooks Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Solid Biosciences Inc. Chief Medical Officer Brooks Gabriel reported an award of 58,847 restricted stock units (RSUs) tied to performance stock units. Each RSU represents a right to receive one share of common stock as it vests. These RSUs relate to the second of four performance milestones under PSUs originally granted on June 11, 2024.
The Board determined that the performance criteria for the second milestone were met on January 29, 2026. The associated RSUs will vest only if Gabriel continues to serve the company through the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
Solid Biosciences Inc. reported that President and CEO Alexander Cumbo acquired 169,401 restricted stock units (RSUs), each representing one share of common stock. These RSUs relate to performance stock units granted on June 11, 2024, which vest in four 25% performance tranches.
The Board determined that the performance criteria for the second Performance Milestone were met on January 29, 2026. Shares tied to this milestone will vest only if Cumbo continues serving with the company through the Evaluation Date, which is anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Technology Officer Paul Herzich acquired 54,925 restricted stock units (RSUs) linked to the company’s common stock as part of his equity compensation. These RSUs were earned under performance stock units (PSUs) originally granted on June 11, 2024.
The PSUs vest in four equal 25% tranches upon achieving independent, pre-set performance milestones tied to business objectives. The Board determined the second milestone was met on January 29, 2026, triggering this 54,925-unit award. These shares will actually vest only if Herzich remains in service on the related Evaluation Date, anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that CFO & Treasurer Kevin Tan acquired 56,647 restricted stock units tied to prior performance-based awards. Each unit represents a contingent right to receive one share of common stock, bringing his directly held RSU-based position reported in this filing to 56,647 units.
These RSUs relate to performance stock units granted on June 11, 2024, which vest in four equal 25% tranches upon achieving predetermined, non-market and non-financial performance milestones. The second milestone was certified as achieved on January 29, 2026, with the associated shares scheduled to vest only if he remains in service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. reported that Chief Regulatory Officer Jessie Hanrahan acquired 54,925 restricted stock units (RSUs) as a compensation grant. Each RSU represents a contingent right to receive one share of Solid Biosciences common stock.
These RSUs relate to performance stock units (PSUs) granted on June 11, 2024. The PSUs vest in four 25% tranches upon achieving independent, Board‑determined performance milestones that are non‑market and non‑financial. The Board determined that the second performance milestone was met on January 29, 2026, and the related shares will vest subject to continued service through an evaluation date anticipated in the first quarter of 2027.
Solid Biosciences Inc. will hold a virtual 2026 Annual Meeting of Stockholders on June 10, 2026 to vote on director elections, auditor ratification and corporate governance proposals. The Board requests votes to elect three Class II directors—Clare Kahn, Adam Stone and Lynne Sullivan—and to ratify the advisory appointment of Ilan Ganot as a Class I director. The Board also asks stockholders to ratify PricewaterhouseCoopers LLP as the independent registered public accounting firm and to approve an amendment to the Certificate of Incorporation to increase authorized common shares from 240,000,000 to 480,000,000. The Board has set the record date as April 16, 2026 and recommends voting "FOR" each proposal.